Meet Medical Oncologist Yuan Yuan, M.D., Ph.D.
Meet Medical Oncologist Yuan Yuan, M.D., Ph.D.

Yuan Yuan, M.D., Ph.D.

  • Associate Professor, Department of Medical Oncology & Therapeutics Research
  • Medical Oncologist
Make an Appointment

Yuan Yuan, M.D., Ph.D.

Clinical Specialties
  • Medical Oncology
Areas of Expertise
  • Breast Cancer
Research Focus
  • Breast Cancer Research
  • Triple Negative Breast Cancer
Other Languages Spoken
  • Mandarin

Yuan Yuan, M.D., Ph.D. is an Associate Professor specializing in breast oncology in the Department of Medical Oncology & Therapeutics.

Prior to joining City of Hope in 2012, she was an assistant professor at Loma Linda University Medical Center in the Division of Medical Oncology and Hematology, and a principal investigator for multiple breast cancer trials. Dr. Yuan received her bachelor of medicine degree from Xuzhou Medical College in Xuzhou, China, and an M.S. in oncology from Peking Union Medical College in Beijing, China. She went on to complete a Ph.D. in biochemistry and molecular biology from the University of California, Riverside. She then completed a research fellowship at the Scripps Research Institute in La Jolla, CA, followed by an internship and residency in internal medicine at the New York University Downtown Hospital in New York, NY. She furthered her training with a hematology and oncology fellowship at the New York University Medical Center, under the direction of Dr. Franco Muggia.

Dr. Yuan’s clinical research interests center on novel therapeutics for metastatic triple negative breast cancer (TNBC). She currently leads multiple clinical trials for metastatic triple negative breast cancer including the following targeted therapies: immune check point inhibitors, androgen receptor targeted therapy, PIK3CA pathway inhibition. She is awarded a STOP CANCER Career Development Award supporting translational research in TNBC tumor evolution and a NIH R03 grant studying biomarkers predicting chemotherapy toxicity in women with breast cancer undergoing chemotherapy. She is experienced in pre-clinical, translational, and clinical application of novel combination therapies. She has worked closely with City of Hope’s translational scientist, molecular pathology core, genomics, bioinformatics and biostatistics core to study the longitudinal genomic mutation profiling of paired metastatic breast cancer. She serves as principle investigator for multiple investigator-initiated trials including a phase II trial combining letrozole, palbociclib and pembrolizumab in patients with HR+ metastatic BC (NCT02778685); a phase I/IB clinical trial studying eribulin plus everolimus in patients with metastatic TNBC (NCT02120469); a phase II trial androgen receptor (AR) targeted therapy GTx-024 in combination with pembrolizumab in patients with metastatic AR+ TNBC; a phase IB study combining ipatasertib with carboplatin or carboplatin/paclitaxel in patients with metastatic TNBC. Her clinical trial work in AR+ TNBC was awarded Phase I Foundation Grant in correlative studies.

Dr. Yuan has multiple publications in peer-reviewed literature and has been invited to present at national and international meetings. She is board certified in internal medicine, hematology and oncology.

Professional Experience

  • 2018 - Present, Associate Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA
  • 2013 - 2017, Assistant Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA
  • 2009 - 2012, Assistant Professor, Division of Medical Oncology and Hematology, Loma Linda University , CA
  • 2006 - 2009, Oncology Fellow, New York University Medical Center, New York, NY.
  • 2003 - 2006, Internal Medicine Intern, New York University Downtown Hospital, New York, NY.
  • 2002 - 2003, Postdoctoral Research Assistant, The Scripps Institute, La Jolla, CA.
  • 1997 - 2002, Doctorate of Philosophy degree, Biochemistry & Molecular Biology, University of California, Riverside, Riverside, CA.
  • 1994 - 1997, Research Assistant, Cancer Institute, Peking Union Medical College, Beijing, China

Member of the Following Care Teams

  • Breast Cancer

Locations

Duarte Google Map Image

Duarte

1500 East Duarte Road, Duarte, CA, 91010

Get Directions

Phone :  626-256-4673

Education

Degrees

  • Ph.D., Biochemistry and molecular biology, University of California, Riverside, CA
  • M.S., Oncology, Peking Union Medical College, Beijing, China
  • Bachelor of Medicine, Xu-Zhou Medical College, Xu-Zhou, China

Fellowship

  • Research Fellowship, Scripps Research Institute in La Jolla, CA
  • Fellowship in Hematology and Oncology, New York University Medical Center, under the direction of Dr. Franco Muggia.

Residency

  • Residency, Internal Medicine, New York University Downtown Hospital in New York, NY

Internship

  • Internship, Internal Medicine, Affiliated Hospital of Xu-Zhou Medical College, Xu-Zhou, China
  • Internship, Internal Medicine, New York University Downtown Hospital in New York, NY

Board Certifications

  • State of California Medical License
  • State of New York Medical License
  • American Board of Internal Medicine
  • American Board of Hematology
  • American Board of Oncology

Publications

Tolaney Sara., Yuan Y., et al. Phase II Trial of Eribulin and Pembrolizumab in TNBC (Submitted 2018)
 
Vincent Chung; Ferdynand J. Kos; Nicola Hardwick, Ph.D.; Yuan Yuan, M.D.; Joseph Chao, M.D.; Daneng Li, M.D.; James Waisman, M.D.; Mengsha Li; Kathryn Zurcher; Paul Frankel; Don J. Diamond, Ph.D.; Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers: Clinical and Translational Oncology (Submitted 06/18)
 
Michelle Afkhami, M.D.; Daniel Benedict Schmolze, M.D.; Susan Yost, Ph.D.; Paul Frankel, Ph.D.; Andrew Dagis, M.S.; Idoroenyi Amanam, M.D.; Milhan Telatar, Ph.D.; Kim Nguyen, Pharm.D.; Kim Wai Yu, Pharm.D.; Thehang Luu, M.D.; Raju Pillai, M.D.; Patricia Aoun, M.D.; Joanne Mortimer, M.D.; Yuan Yuan, M.D., Ph.D.; Mutation and Immune Profiling of Metaplastic Breast Cancer: Correlation with Survival, Breast Cancer Research BRCR-D-18-00296 (Submitted 05/18)
 
Arti Hurria, MD; Enrique Soto-Perez-de-Celis, MD, MSc; Suzette Blanchard; Peggy Burhenn, R.N., M.S., C.N.S.; Christina Haeyoung Yeon, MD; Yuan Yuan, MD, PhD; Daneng Li, MD; Vani Katheria; James Ross Waisman, MD; Thehang H Luu, MD; George Somlo, MD; Anne M Noonan, MD; Ty Lee; Nimit Sudan, MD; Samuel Chung, MD; Arnold Rotter, MD; Anait Arsenyan; Abrahm Levi; Jennifer Choi; Andrea Rubalcava; Rachel Morrison, PhD; Joanne E Mortimer, MD; Efficacy and Tolerability of Nanoparticle Albumin-Bound Paclitaxel in Patients 65 and Older with Locally Advanced or Metastatic Breast Cancer, Breast Cancer Research and Treatment (Submitted Manuscript) April 2018
 
Wang T.Y.,1,2,3, Fahrmann J.F., Lee H., Li Y.J., Tripathi S.C., Yue C., Zhang C., Lifshitz V., Song J., Jandial R., Yuan Y., Somlo G., Ann D., Hanash S., Jove R., Yu H.; JAK/STAT3-Regulated Fatty Acid β-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance. Cell Metabolism. (Accepted January 2018)
 
Kim RM Blenman1*, Ting-Fang He1, Paul H Frankel2, Nora H Ruel2, Erich J Schwartz3, David N Krag4, Lee K Tan5, John H Yim6, Joanne E Mortimer7, Yuan Yuan7, and Peter P Lee
 
Sentinel lymph node B cells can predict disease-free survival in breast cancer patients” (reference number: NPJBCANCER-00276,  submitted to npj Breast Cancer 2018)
 
Yuan Y., Wen W., Yost S., Xing Q., Mortimer J., Yim J.; Synergistic Suppression of Triple Negative Breast Cancer with Combination of PI3K inhibitor Apelisib and CDK4/6 inhibitor Ribociclib (Manuscript Submitted to Cancer Letters 4/17/2018)
 
Gong J, Cho M, Yu KW, Waisman J, Yuan Y, and Mortimer J.  A single institution experience with palbociclib requiring dose modification.   Breast Ca Res and Treat 2018; 168:381-387. PMCID:PMC5838140
 
Bihong T. Chen, MD., Ph.D.; Sean Sethi, MS.; Taihao Jin, Ph.D.; Sunita K. Patel, Ph.D.; Ningrong Ye, MD.; Can-Lan Sun, Ph.D.; Russell Rockne, Ph.D.; Mark Haacke, Ph.D.; James Root, Ph.D.; Andrew J. Saykin, Ph.D.; Tim Ahles, Ph.D.; Andrei Holodny, MD.; Neal Prakash, MD., Ph.D.; Joanne Mortimer, MD.; James Waisman, MD.; Yuan Yuan, MD., Ph.D.; George Somlo, MD.; Daneng Li, MD.; Richard Yang, BS.; Heidi Tan, BS.; Vani Katheria, MS.; Rachel Morrison, Ph.D.; Arti Hurria, MD. Assessing Brain Volume Changes in Older Women with Breast Cancer Receiving Adjuvant Chemotherapy: A Brain MRI Pilot Study. (Accepted to Breast Cancer Research 2018)
 
Bihong T. Chen, MD., Ph.D.; Sean Sethi, MS.; Taihao Jin, Ph.D.; Sunita K. Patel, Ph.D.; Ningrong Ye, MD.; Can-Lan Sun, Ph.D.; Russell Rockne, Ph.D.; Mark Haacke, Ph.D.; James Root, Ph.D.; Andrew J. Saykin, Ph.D.; Tim Ahles, Ph.D.; Andrei Holodny, MD.; Neal Prakash, MD., Ph.D.; Joanne Mortimer, MD.; James Waisman, MD.; Yuan Yuan, MD., Ph.D.; George Somlo, MD.; Daneng Li, MD.; Richard Yang, BS.; Heidi Tan, BS.; Vani Katheria, MS.; Rachel Morrison, Ph.D.; Arti Hurria, MD. Subcortical brain iron deposition and cognitive performance in older women with or without breast cancer receiving adjuvant chemotherapy (Submitted to PLOS One 2018)
 
Arti Hurria, Enrique Soto-Perez-de-Celis, M. Suzette Blanchard, Peggy Burhenn, Christina Haeyoung Yeon, Yuan Yuan, Daneng Li, Vani Katheria, James Waisman, Thehang H Luu, George Somlo, Anne Noonan, Ty Lee, Nimit Sudan, Samuel Chung, Arnold J. Rotter, Anait Arsenyan, Abrahm Levi, Jennifer Choi, Andrea Rubalcava, Rachel Morrison, and Joanne Mortimer, Efficacy and Tolerability of Nanoparticle Albumin-Bound Paclitaxel in Patients 65 and Older with Locally Advanced or Metastatic Breast Cancer (Submitted to JCO 04/2018)
 
Petrossian K., Kanaya N., Hsu P.Y., Yuan Y., Chen S. et al. ERα-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer (Accepted Oncotarget 05/2018)
 
Soto E., Li D., Yuan Y., Lau Y.M., Hurria A.; Functional versus Chronological age: using the Geriatric Assessment to guide decision making in older adults with cancer (Published 06/18 by Lancet Oncology)
 
Yuan, Y., Kos, F.J., He, T.F., Yin, H.H., Li, M., Hardwick, N., Zurcher, K., Schmolze, D., Lee, P., Pillai, R.K. and Chung, V., 2017. Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab. OncoImmunology, 6(12), p.e1363138. (2017)
 
Yuan Y, Vora N, Sun CL, Li D, Smith D, Mortimer J, Luu TH, Somlo G, Waisman J, Chao J, Katheria V, Synold T, Tran V, Mi S, Feng T, Levi A, Arsenyan A, Choi J, Zavala L, Yost S, Hurria A. Association of Pre-Chemotherapy Peripheral Blood Pro-Inflammatory and Coagulation Factors with Physical Function in Women with Breast Cancer. The Oncologist. 2017; 22(10):1189-1196. PubMed [journal] PMID: 28559409, PMCID: PMC5634764
 
Kanaya N, Somlo G, Wu J, Frankel P, Kai M, Liu X, Wu SV, Nguyen D, Chan N, Hsieh MY, Kirschenbaum M, Kruper L, Vito C, Badie B, Yim JH, Yuan Y, Hurria A, Peiguo C, Mortimer J, Chen S. Characterization of patient-derived tumor xenografts (PDXs) as models for estrogen receptor positive (ER+HER2- and ER+HER2+) breast cancers. The Journal of steroid biochemistry and molecular biology. 2017; 170:65-74. NIHMSID: NIHMS785187 PubMed [journal] PMID: 27154416, PMCID: PMC5094906
 
Yuan, Y, N. Vora, C.-L. Sun, D. Li, E. Soto-Perez-de-Celis, J. Mortimer, T.-h. Luu, G. Somlo, J. Waisman, D. Smith, J. Chao, V. Katheria, T. Synold, V. Tran, S. Mi, A. Levi, A. Arsenyan, J. Choi, L. Zavala, S. Yost and A. Hurria (2017). "Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancer." Breast Cancer Research 19(1): 101.
 
Yuan Y, Yost SE, Yuan YC, Solomon NM, Mambetsariev I, Pal S, Frankel P, Salgia R, Neuhausen SL, Mortimer J. Genomic mutation-driven metastatic breast cancer therapy: a single center experience. Oncotarget. 2017; 8(16):26414-26423. PubMed [journal] PMID: 28061482, PMCID: PMC5432268
 
Couples coping with cancer together: a realistic strengths-based strategic program integrated as the standard of medical care for breast cancer Bitz C, Mortimer J, Kruper L, Waisman J, Clark K, Yuan Y, Vito C, Polamero E, Rodriguez J, Hernandez T, Loscalzo M. ISOP; 2017; c 00 . My Bibliography [meeting]
 
A grant funded pilot program changes standard of medical care: supporting metastatic breast cancer patients and partners through enduring audio recording information and couples counseling. Waisman C, Mortimer J, Yuan Y, Vito CK, Helton S, Hernandez T, Polamero E, Loscalzo M. ISOP; 2017; c 00 . My Bibliography [meeting]
 
Yuan, Y., Vora, N., Sun, C.L., Li, D., Soto-Perez-de-Celis, E., Mortimer, J., Somlo, G., Waisman, J., Smith, D., Chao, J. and Katheria, V., 2017. Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancer. Breast Cancer Research, 19(1), p.101. (2017)
 
Gene expression (GE) profiles associated with pathologic complete response (pCR) in locally advanced and inflammatory triple negative (TN) and HER+ (HER2+) breast cancer (BC) pertuzumab (pert), trastuzumab (trast), and nab. Somlo G, Sierra M, Frankel PH, Schmolze D, Treece T, Mortimer JE, Waisman JR, Yuan Y, Yeon CH, Kruper L, Tumyan L, Taylor L, Yim JH, Van Der Baan B, Hurria A, Vito C. ASCO; 2017; c 00 . My Bibliography [meeting]
 
Breast Cancer Index (BCI) prognostic and predictive classification in older vs younger patients with early stage HR+ breast cancer and correlation with clinical risk factors. Yuan Y, Yu C, Israel MA, Liu J, Schnabel CA, Hurria A. ASCO; 2017; c 00 . My Bibliography [meeting]
 
Genomic profiling of metaplastic breast cancer: a single center experience. Afkhami M, Amanam I, Aoun PA, Schmolze D, Yost S, Frankel PH, Nguyen K, Wai Yu W, Luu TH, Yuan Y. ASCO; 2017; c 00 . My Bibliography [meeting]
 
Infections associated with the addition of pertuzumab to trastuzumab-based chemotherapy. Mortimer JE, Yuan Y, Jung JJ, Stewart DB, Chung S, Koehler S, Cooper J, Kruper L, Wong L, Dadwal S. ASCO; 2017; c 00 . My Bibliography [meeting]
 
High risk couples counseling for metastatic breast cancer patients and partners focused on perception of prognosis and early death discussions. Bitz C, Clark K, Mortimer J, Waisman J, Yuan Y, Helton S, Hernandez T, Polamero E, Loscalzo M. American Psychosocial Oncology Society National Conference; 2017 February; c 00 . My Bibliography [meeting]
 
Petrossian K., Kanaya N., Hsu P.Y., Yuan Y., Chen S. et al. Functional ER<alpha> is an important indicator for CDK4/6 inhibitor response in HR+ breast cancer. (Manuscript submitted to Cancer letters 2017)
 
Chen B., Sethi S., Jin T., Yuan Y., Hurria A. et al. Assessing Brain Volume Changes in Older Women with Breast Cancer Receiving Adjuvant Chemotherapy: A Brain MRI Pilot Study. (Manuscript submitted to Breast Cancer Research 2017)
 
Yuan Y., Ferdynand K., He T.F., Yin H., Li M., Zurcher K., Lee P., Pillai R., Chung V., Diamond D.; Resolution of Cutaneous Metastases in a Patient with TNBC after Vaccine Therapy. (Manuscript accepted for publication accepted for publication, Oncoimmunology July 2017)
 
He T., Yost S., Lin F., Chen Z., Mortimer J., Lee P., Yuan Y.; Immune Profiling of Good Risk Versus Poor Risk Triple Negative Breast Cancers (Manuscript in Preparation)
 
He T., Yost S., Lin F., Chen Z., Mortimer J., Lee P., Yuan Y.; Immune Profiling of Paired Primary and Recurrent Triple Negative Breast Cancers (Manuscript in Preparation)
 
Yuan Y., Afkhami M., Yost S., Aoun P., Schmolze D., Frankel P., Amanam I., Nguyen K., Wai Yu K., Liu T., Mortimer J.; Mutational Profiling of Metaplastic Breast Cancer: Potential Indication in Therapy (Manuscript in preparation)
 
Synergistic suppression of triple negative breast cancer with the combination of PI3K inhibitor (alpelisib, BYL719) and CDK inhibitor (ribociclib, LEE011). Yuan Y, Mortimer J, Xing QH, Yan J, Wen W, Han E, Yim J. SABCS; 2016; c 00. My Bibliography [meeting]
 
Kauffmann, R.M., Goldstein, L., Marcinkowski, E., Somlo, G., Yuan, Y., Ituarte, P.H., Kruper, L., Taylor, L. and Vito, C., 2016. Predictors of Antiestrogen Recommendation in Women With Estrogen Receptor–Positive Ductal Carcinoma In Situ. Journal of the National Comprehensive Cancer Network, 14(9), pp.1081-1090.
 
Association of pre-chemotherapy peripheral blood pro-inflammatory (IL-6, CRP) and coagulation (D-dimer) markers with chemotherapy toxicity and reduced dose intensity (RDI) in women with breast cancer Yuan Y, Nilesh V, Sun CL, Li D, Smith D, Mortimer J, Luu T, Somlo G, Waisman J, Chao J, Katheria V, Synold T, Tran V, Mi S, Levi A, Yost S, Arsenyan A, Choi J, Zavala L, Hurria A. SIOG; 2016; c 00 . My Bibliography [meeting]
 
Genomic analysis of molecular discordance of paired primary and recurrent triple negative breast cancer. Yuan Y, Li A, Yost S, Yuan YC, Chu PG, Warden C, Wang JH, Liu Z, Yang Y, Goldstein L, Wu XW. SABCS; 2016; c 00 . My Bibliography [meeting]       
 
Phase II Clinical Trial of Neratinib in patients 60 and older with HER2 over-expressed or mutated breast cancer: trial design considerations for older adults. Yuan Y, Blanchard S, Li DE, Mortimer JE, Waisman J, Somlo G, Yost S, Katheria V, Synold T, Hurria A. SABCS; 2016; c 00 . My Bibliography [meeting]
 
The impact of genomic mutations on metastatic breast cancer treatment: a retrospective clinical trial. Yuan Y, Yost SE, Yuan YC, Yim J, Solomon NM, Mambetsariev I, Pal S, Frankel P, Salgia R, Mortimer JE. SABCS; 2016; c 00 . My Bibliography [meeting]
 
A phase II trial of the addition of pembrolizumab to letrozole and palbociclib in patients with metastatic estrogen receptor positive breast cancer who have stable disease on letrozole and palbociclib. Yuan Y, Frankel P, Synold T, Lee P, Yost S, Waisman J, Somlo G, Hurria A, Mortimer JE. SABCS; 2016; c 00 . My Bibliography [meeting]
 
Femara plus ribociclilb or placebo as neo-adjuvant endocrine therapy for women with ER+, HER2-negative early breast cancer-the feline trial. Khan Q, Mohammad J, Yuan Y, Bardia A, Wisinski K, Baccaray S, Sharma P, Prochaska L, Hard M, Issam M, Wagner J, O'Dea A. SABCS; 2016; c 00 . My Bibliography [meeting]
 
A randomized controlled trial of geriatric assessment guided multidisciplinary interventions: the first year experience. Daneng L, Cynthia K, Trent M, Fakih M, Koczywas M, Cristea M, Pal S, Chung V, Mortimer J, Yuan Y, Burhenn P, Katheria V, Rivera D, Varatkar G, Yu K, Hite S, Mitani D, Ferrell B, Hurria A. SIOG; 2016; c 00 . My Bibliography [meeting]
 
Phase II trial of pertuzumab, trastuzumab, and non-paclitaxel in patients (pts) with HER2 overexpressing (HER2+) locally advanced/inflammatory breast cancer (LABC) or untreated stage IV metastatic breast cancer (MBC). Somlo G, Frankel P, Yeon C, Yuan Y, Yim J, Kruper L, Taylor L, Mortimer J, Jones V, Vito C, Tumyan L, Paz B, Hurria A, Li D, Gaal K, Tong T. SABCS; 2016; c 00 . My Bibliography [meeting]
 
A retrospective pilot study of longitudinal molecular discordance of primary versus recurrent triple negative breast cancer (TNBC). Yuan Y, Wu X, Yost S, Wang J, Liu Z, Yang Y, Goldstein L, Yuan Y. SABCS; 2016; c 00 . My Bibliography [meeting]
 
Breast cancer populations at risk for not receiving chemotherapy. Marcinkowski E, Goldstein L, Polverini A, Yuan Y, Mortimer J, Taylor L, Vito C, Jones V, Yim J, Kruper L. Society of Surgical Oncology Annual Cancer Symposium; 2016; c 00 . My Bibliography [meeting]
 
Association of pre-chemotherapy peripheral blood biomarkers of aging (IL-6, CRP and D-dimer) with chemotherapy toxicity and reduced dose intensity (RDI) in women with breast cancer. Yuan Y, Nilesh V, Sun C, Li D, Mortimer J, Luu T, Somlo G, Waisman J, Chao J, Katheria V, Synold T, Tran V, Mi S, Levi A, Yost S, Arsenyan A, Choi J, Zavala L, Hurria A. National Institute of Aging (NIA) U13 Meeting; 2016; c 00 . My Bibliography [meeting]
 
Egelston C., Simons D., Pillai S., Jimenez G., Avalos C., Butler T., Rozanov D., Spellman P., Melstrom L., Jung J., Yuan Y., Yim J., Lee P.; Identification of tumor-reactive CD8+ T cells in ER+ human breast tumors (Submitted to JNCI December, 2016)
 
Jung J., Almazan T., Lee W., Kauffman R., Cotliar J., Yuan Y., Waisman J., Hurria A., Mortimer J.;  Topical treatment of cutaneous metastatic breast cancer and potential synergy with systemic therapy (submitted to JAMA Dermatology 2016)
 
Chen CH, Cheng CT, Yuan Y, Zhai J, Arif M, Fong LW, Wu R, Ann DK. Elevated MARCKS phosphorylation contributes to unresponsiveness of breast cancer to paclitaxel treatment. Oncotarget. 2015; 6(17):15194-208. PubMed [journal] PMID: 26015406, PMCID: PMC4558145
 
Identification of molecular pathways to define the intake rate of ER+ patient-derived tumor xenografts (PDXs) in NSG mice. Kanaya N, Somlo G, Frankel P, Wu J, Wu SV, Nguyen D, Kai M, Chan N, Hsieh MY, Kirchenbaum M, Kruper L, Vito C, Yuan Y, Hurria M, Mortimer J, Chen S. SABCS; 2015; c 00 . My Bibliography [meeting]
 
Skin, and nail infections associated with the addition of pertuzumab to trastuzumab-based therapy. Mortimer JE, Yuan Y, Jung J, Dadwal S. SABCS; 2015; c 00 . My Bibliography [meeting]
 
Outcome of FoundationOne testing in metastatic breast cancer therapy: a single center experience. Yuan Y, Mortimer JE. SABCS; 2015; c 00 . My Bibliography [meeting]
 
The combination of eribulin and everolimus results in enhanced suppression of tumors in mouse models of triple negative breast cancer. Marcinkowski E, Luu T, Yuan Y, Mortimer J, Leong L, Portnow J, Xing Q, Wen W, Yim JH. SABCS; 2015; c 00 . My Bibliography [meeting]
 
Molecular characterization of CDK 4/6 inhibitors (plabociclib, abemaciclib, and ribociclib) in hormone receptor-positive breast cancer cell lines. Petrossian K, Lo C, Yuan Y, Chen S. SABCS; 2015; c 00 . My Bibliography [meeting]
 
Phase II trial of neoadjuvant chemotherapy with carboplatin and nab-paclitaxel in patients with triple negative locally advanced and inflammatory breast cancer. Somlo G, Chung S, Frankel P, Hurria A, Koehler S, Kruper L, Mortimer JE, Paz B, Robinson K, Taylor L, Vito C, Waisman J, Yeon C, Yim J, Yuan Y, Tong T. SABCS; 2015; c 00 . My Bibliography [meeting]
 
Association of the baseline pro-inflammatory (IL-6, CRP) and coagulation (D-dimer) markers with relative dose intensity (RDI) in women with breast cancer (BC) undergoing (neo) adjuvant chemotherapy (chemo). Yuan Y, Voral N, Hurria A. Annual ASCO Meeting; 2015; c 00 . My Bibliography [meeting]
 
Skin, nail and staphylococcal infections associated with the addition of pertuzumab to trastuzumab-based chemotherapy. Mortimer JE, Jung J, Yuan Y, Kruper L. Annual ASCO Meeting; 2015; c 00 . My Bibliography [meeting]
 
MARCKS phosphorylation is associated with breast cancer malignancy and paclitaxel unresponsiveness. Chen CH, Cheng CT, Yuan Y, Wu R, Ann D. Annual ASCO Meeting; 2015; c 00 . My Bibliography [meeting]
 
Acceptance of chemotherapy recommendation in patients with early-stage breast cancer Marcinkowski EF, Kauffmann RM, Ottesen R, Niland J, Yuan Y, Kruper L, Taylor L, Somlo G, Waisman J, Kim J, Vito C. Society of Surgical Oncology Annual Meeting; 2015 March; Houston, Texas. c 00 . My Bibliography [meeting]
 
Predictors of tamoxifen use in women with estrogen-receptor positive ductal carcinoma in-situ Kauffmann R, Marcinkowski E, Goldstein L, Somlo G, Yuan Y, Ituarte P, Kruper L, Taylor L, Vito C. Society of Surgical Oncology Annual Meeting; 2015 March; Houston, Texas. c 00 . My Bibliography [meeting]
 
Mortimer J, Jung J, Yuan Y, Kruper L, Stewart D, Chung S, Yu KW, Mendelsohn M, D'Apuzzo M, Tegtmeier B, Dadwal S. Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy. Breast cancer research and treatment. 2014; 148(3):563-70. PubMed [journal] PMID: 25385180, PMCID: PMC4243002
 
Khan S, Bennit HF, Turay D, Perez M, Mirshahidi S, Yuan Y, Wall NR. Early diagnostic value of survivin and its alternative splice variants in breast cancer. BMC cancer. 2014; 14:176. PubMed [journal] PMID: 24620748, PMCID: PMC3995700
 
Association of baseline pro-inflammatory (IL-6, CRP) and coagulation (D-dimer) markers with baseline functional status in women with breast cancer (BC) undergoing chemotherapy. Yuan Y, Hurria A. SABCS; 2014; c 00 . My Bibliography [meeting]
 
Skin infections associated with the addition of pertuzumab to trastuzumab-containing chemotherapy.
 
Mortimer JE, Yuan Y, Stewart D, Chung S, Kruper L, Wong LC, Mendelsohn M, Behrendt C, Dadwal S, Tegtmeier B. SABCS; 2014; c 00 .  My Bibliography [meeting]
 
Accrual of under-represented minority women to breast cancer clinical trials in Inland Empire, California. Yuan Y, Uppala P. ASCO Breast Cancer Symposium; 2012 September; c 00 . My Bibliography [meeting]
 
Yuan Y, Cohen DJ, Love E, Yaw M, Levinson B, Nicol SJ, Hochster HS. Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors. Cancer chemotherapy and pharmacology. 2011; 68(2):371-8. PubMed [journal] PMID: 20978761
 
Yuan Y, Liao YM, Hsueh CT, Mirshahidi HR. Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. Journal of hematology &amp; oncology. 2011; 4:16. PubMed [journal] PMID: 21504625, PMCID: PMC3103487
 
Yuan Y, Uppla P. Accrual of underrepresented minority women to breast cancer clinical trials in the inland empire California. Journal of clinical oncology. 2011; 29. My Bibliography [journal]
 
Yuan Y, Wieczorek R, Green DL, Cook P, Ballard H, Araten DJ. Multiple myeloma involving skin and pulmonary parenchyma after autologous stem cell transplantation. Journal of hematology &amp; oncology. 2009; 2:48. PubMed [journal] PMID: 19912647, PMCID: PMC2788580
 
Yuan Y, Ma H, Cohen D, Hochster HS. Activity and tolerance of biweekly CapeOx-Cetuximab in 1st line therapy of metastatic colorectal cancer (mCRC): relation to K-ras mutation status. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009; 27. My Bibliography [journal]
Petrovan RJ, Yuan Y, Curtiss LK. Expression of the Lyst(beige) mutation is atheroprotective in chow-fed apolipoprotein E-deficient mice. Journal of lipid research. 2008; 49(2):429-37. PubMed [journal] PMID: 17982137
 
Yuan Y, Orlow SJ, Curtin J, Downey A, Muggia F. Pegylated liposomal doxorubicin (PLD): enhanced skin toxicity in areas of vitiligo. Ecancermedicalscience. 2008; 2:111. PubMed [journal] PMID: 22275986, PMCID: PMC3234058
 
Cohen D, Ma H, Yuan Y, Hochman T, Hochster HS. Biweekly cetuximab (C), oxaliplatin (Ox), and capecitabine (Cape) in first line therapy of metastatic colorectal cancer (mCRC): preliminary results on toxicity and K-ras status. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008; 26. My Bibliography [journal]
 
A relapsed multiple myeloma with multiple soft tissue plasmacytoma of the extremities and diffuse pulmonary parenchymal involvement. Yuan Y, Omene C, Green D, Araten D, Ballard H. Annual Research Conference of Department of Medicine; 2008; c 00 . My Bibliography [meeting]
 
Zhu Y, Liao H, Xie X, Yuan Y, Lee TS, Wang N, Wang X, Shyy JY, Stemerman MB. Oxidized LDL downregulates ATP-binding cassette transporter-1 in human vascular endothelial cells via inhibiting liver X receptor (LXR). Cardiovascular research. 2005; 68(3):425-32. PubMed [journal] PMID: 16099444
 
Artherosclerosis in apolipoprotein e-deficient mice with the lystheige mutation. Petrovan RJ, Yuan Y, Curtiss LK. Annual Research Conference of Department of Medicine; 2004; c 00 . My Bibliography [meeting]
 
Zhu Y, Liao HL, Niu XL, Yuan Y, Lin T, Verna L, Stemerman MB. Low density lipoprotein induces eNOS translocation to membrane caveolae: the role of RhoA activation and stress fiber formation. Biochimica et biophysica acta. 2003; 1635(2-3):117-26. PubMed [journal] PMID: 14729074
 
Yuan Y, Verna LK, Wang NP, Liao HL, Ma KS, Wang Y, Zhu Y, Stemerman MB. Cholesterol enrichment upregulates intercellular adhesion molecule-1 in human vascular endothelial cells. Biochimica et biophysica acta. 2001; 1534(2-3):139-48. PubMed [journal] PMID: 11786300
 
Cholesterol-induced cell signaling in the endothelium. Yuan Y, Wang N, Zhu Y, Liao HL, Stemerman MB, Verna LK. International Society of Thrombosis and Homeostasi; 2001 July 08; Paris, France. c 00 . My Bibliography [meeting]
 
Zhu Y, Liao HL, Wang N, Yuan Y, Ma KS, Verna L, Stemerman MB. Lipoprotein promotes caveolin-1 and Ras translocation to caveolae: role of cholesterol in endothelial signaling. Arteriosclerosis, thrombosis, and vascular biology. 2000; 20(11):2465-70. PubMed [journal] PMID: 11073854
 
Cholesterol causes human umbilical vein endothelial cell activation Yuan Y, Stemerman MB. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2000; 14(4):A414. My Bibliography [journal]
 
Photodynamic therapy induced cell apoptosis Yuan Y, Zhou CN. Chinese Journal of Laser Medicine. 1996; 5(2):111-115. My Bibliography [journal]

Memberships

  • American Society of Hematology
  • American Society of Clinical Oncology
  • Southwest Oncology Group
  • SWOG Breast Committee
  • Cancer Trials Support Unit
Back To Top